Healthcare It News
OmniAb, the antibody division of Ligand Pharmaceuticals, is set to go public via a SPAC merger that can infuse the enterprise with as much as $266 million. The deal comes as traditional IPOs have principally ground to a halt as a end result of uncertain market circumstances, but Ligand is making a longer-term guess on […]
Continue Reading